We are pleased to announce a new webinar on COVID-19, live on Monday, August 3! Sacha Gnjatic, co-director of the Human Immune Monitoring Center at Mount Sinai, will explain why inflammatory cytokines and SARS-CoV-2 antibody responses can predict survival and severity in COVID-19. Don't miss the opportunity to get new insights and ask your questions!
Inflammatory cytokines and SARS-CoV-2 antibody responses predict survival and severity in COVID-19
Date: August 3, 2020
Time: 16:00 (CEST)
In this webinar, Sacha Gnjatic will cover both innate and adaptive immune aspects potentially driving pathology following SARS-CoV-2 infection. Applying their immune monitoring experience to large patient cohorts hospitalized at Mount Sinai in New York during the COVID-19 epidemic, Sacha Gnjatic and his team investigated cytokine and antibody profiles. They found that levels of IL-6, TNF-alpha, and antiviral immunoglobulins are helpful in predicting severity and survival outcome, and may be useful to stratify patients and guide tailored therapies. Sacha Gnjatic is an associate professor and the co-director of the Human Immune Monitoring Center at Mount Sinai. As a tumor immunologist, he specializes in studying immune correlates, both circulating and tissue-based, to define biomarkers of immunotherapies from human clinical trials.
The webinar will be moderated by Miriam Merad, the Mount Sinai Chair professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York. Miriam Merad is the Vice-President of IUIS.